Key facts
- 4Tissue’s last known valuation is $5.2M (Feb 2025).
- It has raised $3.8M; the latest was Accelerator/Incubator in Apr 2025.
- Notable investors include European Innovation Council, Annemie Van De Casteele, Ghent University, Griet Nuytinck, Virginie Saverys.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for 4Tissue
- ·The full record, as it builds
Funding rounds
No funding rounds for 4Tissue are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 4Tissue
Developer of regenerative medical technology intended for tissue reconstruction and regeneration. The company develops bioresorbable hydrogel systems for soft-tissue regeneration, particularly in breast reconstruction, enabling healthcare providers to support natural tissue formation in patients.
- Sector
- Healthcare
- HQ
- Zwijnaarde, Belgium
- Founded
- 2023
- Employees
- 9
- Website
- 4tissue.com/
- Ownership
- Privately Held (backing)
4Tissue doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 4Tissue shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 4Tissue in its N-PORT filings yet. We sweep new filings monthly.